Clinical Trial Update: LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung [Phase 2]

View source ↗

Summary

Phase IIb trial comparing afatinib to gefitinib as first-line treatment for EGFR mutation-positive adenocarcinoma of the lung has completed with results posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• Afatinib (afatinib)
• Gefitinib (Gefitinib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Lung Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2017-06-19